Condition: Metastatic Castration-resistant Prostate Cancer · Sponsor: Daiichi Sankyo
This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).
This description comes directly from the study's public registry record.
Contact for Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| University of California San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Beth Isreal Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Newton, Massachusetts, United States | Recruiting |
| Cancer & Hematology Center | Grand Rapids, Michigan, United States | Recruiting |
| Northwell Health Cancer Institute (START NY) | Lake Success, New York, United States | Recruiting |
| Carolina Urologic Research Center | Myrtle Beach, South Carolina, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| Virginia Cancer Specialists (NEXT Virginia) | Fairfax, Virginia, United States | Recruiting |
| Medical College Of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
| Sun Yatsen University Cancer Center | Guangzhou, China | Recruiting |
| Fudan University Shanghai Cancer Center - Xuhui District | Shanghai, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07244341